Atomo Diagnostics

We are a global company. From our research, development and corporate office in Sydney, Australia; with production capabilities in the U.S.A. and manufacture and distribution in South Africa - we are Atomo.

Atomo Diagnostics wishes to remind our colleagues in the medical diagnostic industry that our COO, Chandra Sukumar will be in Düsseldorf this coming Monday, November 11, for the annual #MEDICA Trade Show. Chandra still has some availability left over the course of the 3 days. If you would like to meet with her to discuss Atomo's innovative solutions, customisation options and development pathways, please email her at [email protected] or contact her on LinkedIn. See you next week!

We are excited to announce that Chandra Sukumar, Chief Operations Officer of Atomo Diagnostics, will be attending #MEDICA 2024 in Düsseldorf from November 11–14. This is a unique opportunity to explore our innovative solutions, customisation options and development pathways firsthand. If you would like to meet with Chandra, please reach out to her at [email protected] or contact her on LinkedIn. Don’t miss this chance to connect with us! See you at MEDICA!

ICYMI: CEO and Managing Director, John Kelly, gave a presentation of Atomo's Q1 Results for FY25. To view the presentation, click the link below. https://lnkd.in/gPS2yBhh

Atomo Diagnostics wishes to extend an invitation to all shareholders and interested parties to our Q1 FY25 results webinar hosted by CEO John Kelly. The webinar will take place this coming Tuesday, October 29 at 2PM AEDT. The presentation is expected to take approximately 20 minutes with 10 further minutes assigned for Q&A. Please submit all questions in advance to [email protected] To register for the webinar, click the link below. https://lnkd.in/euE5fHYy

Atomo is pleased to announce receiving a $2.44 million Government CRC-P grant to spearhead the development of a groundbreaking rapid test for active syphilis diagnosis. The grant award follows many months of collaboration between Atomo, The Burnet Institute and IDE Group on an easy-to-use solution that addresses this important unmet clinical need. This unique test, designed for both point-of-care professional use and at-home self-testing, combines Atomo’s proven integrated Pascal cassette that works with a small finger prick blood sample and a unique syphilis antibody assay developed by the Burnet Institute.   The assay distinguishes active infections from previously treated cases.  This pioneering rapid test will represent a first for the global market, with existing rapid Syphilis tests only detecting antibodies present in both active infections and prior treated infections, and with no rapid Syphilis test currently approved for self-test use in Australia. Special congratulations to Rohit Ketkar, Dr. Mohammad Imran, PhD and Professor Heidi Drummer who put the grant submission together as well as John Kelly, Chandra Sukumar and Jennifer Barnes for their support throughout the submission process. After making such a significant contribution to addressing the HIV epidemic, Atomo Diagnostics is incredibly excited to begin tackling another critical public health issue. Read the ASX Release at the link below. https://lnkd.in/eJmd9wGH

Atomo Diagnostics Limited (ASX: AT1) is pleased to announce the release of its Annual Report for 2024. The report provides a comprehensive overview of the company’s financial performance, operational achievements, and strategic initiatives throughout the year. It highlights Atomo's continued commitment to innovation in the field of rapid diagnostic testing, its partnerships, and its ongoing efforts to address global health challenges. Key sections of the report include updates on the company’s expansion into new markets, the development of new products, and strategic collaborations aimed at improving access to essential diagnostic tools. Atomo’s commitment to OEM and development solutions for healthcare providers is also emphasised, alongside its ambition to continue playing a significant role in global health. To read the full report and gain deeper insights into Atomo’s performance and vision for the future, please click the link below: https://lnkd.in/g7nzWs8t

Atomo is pleased to note that Lumos Diagnostics has secured US$2.98m in funding from the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services. Funding will be primarily used to conduct a planned clinical trial and regulatory submission for Lumos' FebriDx® test to secure CLIA-Waiver. Doug Ward, CEO and Managing Director of Lumos Diagnostics, said “We are honoured to have the opportunity to partner with BARDA on the CLIA waiver study and regulatory submission for FebriDx®.  Should this goal be achieved, FebriDx’s ability to improve antibiotic stewardship will be vastly expanded.” Atomo welcomes further funding being allocated to support Lumos' CLIA-Waiver program for the FebriDx test, recognising that CLIA-Waiver for the test based on the Pascal cassette significantly increases the market for supply of Pascal to Lumos as well as establishing a de-risked regulatory pathway in the US for other applications seeking access to Pascal for deployment in CLIA-Waived settings.

On Tuesday, our team in Cape Town celebrated Heritage Day. On this day, South Africans honour their cultural heritage and the rich diversity of their beliefs and traditions, recognising that the nation belongs to all. Atomo's Office Manager in Cape Town, Hanszeline Jennifer Howburg, writes: "Yearly we celebrating Heritage Day on the 24 September, the rich tapestry of cultures, traditions, languages, art and values that unite us as South Africans and connect us to the world. We dressed in designs of our own choices in creativity and connection by celebrating the great time. It was a day of colour, fun and unity that showcasing the power of teamwork and values." We love seeing the celebrations from our operations team in South Africa and deeply value their contribution to the organisation. Nothing we do at Atomo would be possible without them!

Syphilis is arguably the largest sexual health concern facing Australia and other parts of the world. With reported cases having tripled in Australia over the past 10 years and 8 million reported cases in adults aged between 15-49 globally in 2022 alone, there is a critical need for increased awareness, testing, and prevention efforts to address this escalating health issue. Learn more about symptoms, diagnosis and treatment of syphilis in our new article titled Syphilis 101: Early Signs, Diagnosis, and Why Testing Matters https://lnkd.in/evvUF-kk